(Q24202329)

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

A five year study of bacteriology and prophylactic chemotherapy in patients with chronic bronchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Effect of antibiotics on purulent sputum in chronic bronchitis and bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

INFLUENCE OF DAILY PENICILLIN, TETRACYCLINE, ERYTHROMYCIN, AND SULPHAMETHOXYPYRIDAZINE ON EXACERBATIONS OF BRONCHITIS. A REPORT TO THE RESEARCH COMMITTEE OF THE BRITISH TUBERCULOSIS ASSOCIATION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Continuous suppressive antimicrobial treatment in chronic infected bronchitis during the winter months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Ampicillin and tetracycline in the treatment and prophylaxis of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Five-year winter chemoprophylaxis for chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Sulphonamide prophylaxis in chronic bronchitis; a clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Prophylactic antibiotic therapy in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Evaluation of Continuous Antibiotic Therapy in Chronic Bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Controlled trials of a sulphonamide given weekly to prevent exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Prevention of exacerbations of bronchitis: Trial of a long acting sulphonamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Daily single-dose regimen and alternate-two-week triple-dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

A double-blind cross-over trial of trimethoprim and sulphamethoxazole in chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

A measure of quality of life for clinical trials in chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Using numerical results from systematic reviews in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Development and first validation of the COPD Assessment Test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Global burden of COPD: risk factors, prevalence, and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Prophylactic antibiotic therapy for chronic bronchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

COPD exacerbations . 2: aetiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Antibiotic prevention of acute exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

Long-Term Tetracycline Treatment of Chronic Bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Bacterial infection and some effects of chemoprophylaxis in chronic pulmonary emphysema. I. Chemoprophylaxis with intermittent tetracycline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Prophylactic chemotherapy in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Long-term oxytetracycline (terramycin) therapy in advanced chronic respiratory infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Long-term prophylactic administration of tetracycline to chronic bronchitics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

A trial of continuous winter chemotherapy in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Trimethoprim prophylaxis of acute exacerbations in chronic obstructive pulmonary diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Chemotherapy in chronic bronchitis. Influence of daily penicillin and tetracycline on exacerbations and their cost

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on trials of chemotherapy in early chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Adult chronic bronchitis: continuous antibiotic therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

A Trial of Phenethicillin in Chronic Bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

Erythromycin and common cold in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009764.PUB2

7 January 2021

10.1002/14651858.CD009764.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

24288145

1 reference

Consolidated OpenCitations Corpus – April 2017